Acquiring Company
Supernus Pharma
Acquired Company
Indivior
RockvilleBiotechnologyHealth CareTherapeuticsPharmaceuticalBiotechnologyHealth CareMedicalPharmaceuticalDescription
Supernus Pharma and Indivior have signed an all-stock merger agreement to create a new company focused on CNS diseases, with projected revenues of $2.2 billion. Indivior shareholders will receive a $1 billion cash dividend, and ownership will be split 56.5% for Indivior and 43.5% for Supernus. The merger is expected to enhance growth initiatives and create value for stockholders.
Related People
M&A Insights
Based on deal dataFrequently asked
Who acquired Indivior?
Indivior was acquired by Supernus Pharma, based in Rockville. The deal was reported on August 3, 2026. Supernus Pharma focuses on developing and commercializing products for central nervous system diseases. It offers a portfolio of medicines for ADHD, depression, Parkinson's disease, epilepsy, and migraine. Supernus Pharma is privately held and operates in Biotechnology.
When did Supernus Pharma acquire Indivior?
Supernus Pharma's acquisition of Indivior was reported on August 3, 2026. Supernus Pharma and Indivior have signed an all-stock merger agreement to create a new company focused on CNS diseases, with projected revenues of $2.2 billion. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Indivior do?
Indivior Pharmaceuticals, Inc. specializes in the treatment of addiction and is engaged in developing medicines to help individuals with substance use disorders. It is publicly traded (INDV), operating in Biotechnology.